Epizyme, Inc. (EPZM)
Price:
1.47 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
NEWS
Ipsen to acquire Epizyme, expanding its portfolio in oncology
globenewswire.com
2023-05-19 05:20:00PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients.
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
globenewswire.com
2023-05-18 15:54:00PARIS, FRANCE, 5 August 2022 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged.
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
globenewswire.com
2023-05-18 00:55:00PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close.
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
businesswire.com
2022-08-12 11:35:00PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close. As part of the trans
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
zacks.com
2022-08-10 16:33:05Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-09 09:47:29Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
businesswire.com
2022-08-09 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
businesswire.com
2022-08-05 01:00:00PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
businesswire.com
2022-07-12 19:26:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A. (OTC: IPSEY). Under the terms of the proposed transaction, shareholders of Epizyme will receive only $1.45 in cash plus a CVR (Contingent Value Right) of $1.00 for each share of Epizyme that they own. KSF is seeking to determine whether this consideration and the pr
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
headlinesoftoday.com
2022-07-06 23:16:00NEW YORK, July 6, 2022 /PRNewswire/ — If you own shares in any of the companies listed above and would like to discuss our investigations or have any...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Epizyme, Inc. Merger
newsfilecorp.com
2022-06-28 10:31:00Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating Epizyme, Inc. ("Epizyme") (NASDAQ: EPZM) regarding possible breaches of fiduciary duties and other violations of law related to Epizyme's agreement to be acquired by Ipsen S.A. (OTC Pink: IPSEF). Under the terms of the agreement, Epizyme's shareholders will receive $1.45 in cash and one contingent value right (CVR) of $1.00 for each share of Epizyme common stock they own.To learn more about...
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM
prnewswire.com
2022-06-27 21:30:00NEW YORK , June 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Epizyme, Inc. (EPZM), relating to its proposed acquisition by Ipsen S.A. via a tender offer.
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.
prnewswire.com
2022-06-27 16:57:00NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. ("Epizyme" or the "Company") (NASDAQ: EPZM), in connection with the proposed acquisition of the Company by Ipsen S.A. (Euronext: IPN; ADR: IPSEY) via tender offer.
Why Epizyme Stock Is Soaring Today
fool.com
2022-06-27 12:24:48A buyout ends Epizyme's 15-year tenure as an independent biopharma.
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen
prnewswire.com
2022-06-27 11:38:00MILWAUKEE , June 27, 2022 /PRNewswire/ -- Ademi LLP is investigating Epizyme (NASDAQ:EPZM) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click here to learn how to join the action: https://www.ademilaw.com/case/epizyme-inc or call Guri Ademi toll-free at 866-264-3995.
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
businesswire.com
2022-06-27 08:56:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Epizyme, Inc. (NASDAQ: EPZM) to Ipsen is fair to Epizyme shareholders. Halper Sadeh encourages Epizyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Epizyme and its board of directors violated the federal sec
No data to display
Ipsen to acquire Epizyme, expanding its portfolio in oncology
globenewswire.com
2023-05-19 05:20:00PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients.
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
globenewswire.com
2023-05-18 15:54:00PARIS, FRANCE, 5 August 2022 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged.
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
globenewswire.com
2023-05-18 00:55:00PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close.
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
businesswire.com
2022-08-12 11:35:00PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close. As part of the trans
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
zacks.com
2022-08-10 16:33:05Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-09 09:47:29Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
businesswire.com
2022-08-09 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
businesswire.com
2022-08-05 01:00:00PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
businesswire.com
2022-07-12 19:26:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A. (OTC: IPSEY). Under the terms of the proposed transaction, shareholders of Epizyme will receive only $1.45 in cash plus a CVR (Contingent Value Right) of $1.00 for each share of Epizyme that they own. KSF is seeking to determine whether this consideration and the pr
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
headlinesoftoday.com
2022-07-06 23:16:00NEW YORK, July 6, 2022 /PRNewswire/ — If you own shares in any of the companies listed above and would like to discuss our investigations or have any...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Epizyme, Inc. Merger
newsfilecorp.com
2022-06-28 10:31:00Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating Epizyme, Inc. ("Epizyme") (NASDAQ: EPZM) regarding possible breaches of fiduciary duties and other violations of law related to Epizyme's agreement to be acquired by Ipsen S.A. (OTC Pink: IPSEF). Under the terms of the agreement, Epizyme's shareholders will receive $1.45 in cash and one contingent value right (CVR) of $1.00 for each share of Epizyme common stock they own.To learn more about...
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM
prnewswire.com
2022-06-27 21:30:00NEW YORK , June 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Epizyme, Inc. (EPZM), relating to its proposed acquisition by Ipsen S.A. via a tender offer.
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.
prnewswire.com
2022-06-27 16:57:00NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. ("Epizyme" or the "Company") (NASDAQ: EPZM), in connection with the proposed acquisition of the Company by Ipsen S.A. (Euronext: IPN; ADR: IPSEY) via tender offer.
Why Epizyme Stock Is Soaring Today
fool.com
2022-06-27 12:24:48A buyout ends Epizyme's 15-year tenure as an independent biopharma.
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen
prnewswire.com
2022-06-27 11:38:00MILWAUKEE , June 27, 2022 /PRNewswire/ -- Ademi LLP is investigating Epizyme (NASDAQ:EPZM) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click here to learn how to join the action: https://www.ademilaw.com/case/epizyme-inc or call Guri Ademi toll-free at 866-264-3995.
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
businesswire.com
2022-06-27 08:56:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Epizyme, Inc. (NASDAQ: EPZM) to Ipsen is fair to Epizyme shareholders. Halper Sadeh encourages Epizyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Epizyme and its board of directors violated the federal sec